Shanghai Yizhong Pharmaceutical Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Public
- Established
- 2009-09-10
- Employees
- 304
- Market Cap
- -
- Website
- http://www.yizhongpharma.com
Polymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer
Phase 3
Not yet recruiting
- Conditions
- Pancreatic Cancer Metastatic
- Interventions
- First Posted Date
- 2024-12-31
- Last Posted Date
- 2025-01-01
- Lead Sponsor
- Shanghai Yizhong Pharmaceutical Co., Ltd.
- Target Recruit Count
- 416
- Registration Number
- NCT06752811
- Locations
- 🇨🇳
Jiangsu Province Hospital, Nanjing, Jiangsu, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer
Phase 3
Recruiting
- Conditions
- Metastatic Breast Cancer (MBC)
- Interventions
- First Posted Date
- 2023-11-22
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Shanghai Yizhong Pharmaceutical Co., Ltd.
- Target Recruit Count
- 168
- Registration Number
- NCT06143553
- Locations
- 🇨🇳
Jiangsu province Hospital, Nanjing, Jiangsu, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Paclitaxel Micelles for Injection / Paclitaxel Injection in Combination With Cisplatin for First-line Therapy of Advanced NSCLC
Phase 3
- Conditions
- Non-Small Cell Lung Cancer(NSCLC)
- Interventions
- First Posted Date
- 2016-01-29
- Last Posted Date
- 2021-03-17
- Lead Sponsor
- Shanghai Yizhong Pharmaceutical Co., Ltd.
- Target Recruit Count
- 454
- Registration Number
- NCT02667743
- Locations
- 🇨🇳
Guangdong General Hospital, Guangzhou, Guangdong, China
🇨🇳Shanghai Chest Hospital, Shanghai, Shanghai, China
🇨🇳Jiangsu Cancer Hospital, Nanjing, Zhejiang, China
© Copyright 2025. All Rights Reserved by MedPath